Kenvue Inc. (NYSE:KVUE) Shares Sold by Byrne Asset Management LLC

Byrne Asset Management LLC trimmed its position in Kenvue Inc. (NYSE:KVUE) by 1.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,846 shares of the company’s stock after selling 827 shares during the period. Kenvue makes up about 1.0% of Byrne Asset Management LLC’s portfolio, making the stock its 28th largest holding. Byrne Asset Management LLC’s holdings in Kenvue were worth $1,342,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Grove Bank & Trust boosted its holdings in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Kenvue during the 4th quarter worth $29,000. Riverview Trust Co acquired a new position in shares of Kenvue in the 3rd quarter worth $30,000. Fortitude Family Office LLC grew its holdings in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue during the third quarter worth $35,000. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

KVUE stock opened at $20.23 on Friday. The firm has a 50 day moving average of $21.61 and a two-hundred day moving average of $21.93. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a market capitalization of $38.79 billion, a price-to-earnings ratio of 38.17, a P/E/G ratio of 2.16 and a beta of 1.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities analysts anticipate that Kenvue Inc. will post 1.05 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 4.05%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Analysts Set New Price Targets

A number of research firms recently weighed in on KVUE. Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. UBS Group reduced their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.